Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Marathon Petroleum Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Marathon Petroleum Corp trades at $294.92 (market cap $82.83B). The key difference: Marathon Petroleum Corp is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Marathon Petroleum Corp pays a 1.38% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MPC | |
|---|---|---|
Market Cap | $39.89B | $82.83B |
Sector | Health | Energy |
52-Week High | $491.22 | $283.74 |
52-Week Low | $278.09 | $158.59 |
Enterprise Value | $38.15B | $115.01B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Marathon Petroleum (MPC) trades at $283.74, up 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong profitability with 27.92% ROE and attractive valuation metrics including P/E of 18.68 and P/S of 0.63. Recent earnings beat expectations in Q4 2025 and Q1 2026, while refining capacity constraints and Middle East tensions provide tailwinds for the energy sector.
MPC presents a compelling value opportunity with solid fundamentals and positive analyst sentiment, though investors face risks from volatile oil prices, regulatory scrutiny over pricing practices, and declining revenue trends. The stock trades near analyst consensus target of $278.38 with 76% buy ratings supporting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
